SubsidieMeestersThe first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market
The Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation.
Projectdetails
Introduction
The Realheart TAH system (RTS) is the first total artificial heart designed to mimic the structure and function of the human heart.
Design and Features
Its unique patented construction of two atria and two ventricles is separated by an atrioventricular plane which contains the valves, enabling it to pump blood naturally whilst reducing the risk of blood flow complications.
Efficiency and Adaptability
RTS is designed to be:
- Efficient (12h battery)
- Silent
- Lightweight (2.5kg)
- Easy to implant
- Automatically adaptable to different physiological activity levels
Components
It consists of:
- Two identical artificial heart pumps
- A drive line
- An intelligent control unit
RTS is connected via a cable through the skin to a controller carried together with two batteries in a belt around the waist.
Target Patients
RTS is aimed as a permanent solution for:
- End-stage heart failure patients
- Patients waiting for a transplant
Future Plans
Realheart will complete GLP animal trials, clinical trial preparatory activities, and the first-in-man (EFS) trial during the EIC project.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 38.241.965 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- SCANDINAVIAN REAL HEART ABpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)Carmat's Aeson® is an advanced total artificial heart designed to replace native ventricles, offering a physiological alternative to heart transplants for advanced heart failure patients. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patientsSyntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)
Carmat's Aeson® is an advanced total artificial heart designed to replace native ventricles, offering a physiological alternative to heart transplants for advanced heart failure patients.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
De ontwikkeling van een slimme katheterDit project ontwikkelt een slimme hartkatheter en een realistisch testplatform om de efficiëntie van katheterablatie te verbeteren, wat leidt tot meer kennis en werkgelegenheid in Zuid-Nederland. | Mkb-innovati... | € 132.538 | 2018 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
De ontwikkeling van een slimme katheter
Dit project ontwikkelt een slimme hartkatheter en een realistisch testplatform om de efficiëntie van katheterablatie te verbeteren, wat leidt tot meer kennis en werkgelegenheid in Zuid-Nederland.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.